In the case of advanced non-small cell lung cancer (NSCLC), a significant difference in response to the kinase inhibitor gefitinib (Iressa) was observed for patients with mutations or amplifications in the EGFR gene [55,56]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.